|
|
(21 intermediate revisions not shown) |
Line 1: |
Line 1: |
| <html> | | <html> |
- |
| |
- | <head>
| |
| | | |
| <style> | | <style> |
Line 557: |
Line 555: |
| | | |
| <div style='mso-element:para-border-div;border:none;border-bottom:solid #4F81BD 1.0pt; | | <div style='mso-element:para-border-div;border:none;border-bottom:solid #4F81BD 1.0pt; |
- | mso-border-bottom-themecolor:accent1;padding:0cm 0cm 4.0pt 0cm'> | + | mso-border-bottom-themecolor:accent1;padding:0cm 1cm 4.0pt 0cm'> |
| | | |
- | <p class=MsoTitle align=center style='text-align:center'><span lang=EN-US>IIT | + | <p align=center><embed src="https://static.igem.org/mediawiki/igem.org/5/51/Nish1.swf" width=900 height=500></p> |
- | Delhi iGEM Wiki</span></p>
| + | |
- | | + | |
- | </div>
| + | |
- | | + | |
- | <p class=MsoNormal><span lang=EN-US><o:p> </o:p></span></p>
| + | |
- | | + | |
- | <h2><u><span lang=EN-US>Renin Angiotensin Aldosterone System (RAAS)<o:p></o:p></span></u></h2>
| + | |
- | | + | |
- | <p class=MsoNormal><span lang=EN-US><o:p> </o:p></span></p>
| + | |
- | | + | |
- | <h3><span lang=EN-US>Introduction</span></h3>
| + | |
- | | + | |
- | <p class=MsoNormal style='text-align:justify'><span lang=EN-US>The Renin
| + | |
- | Angiotensin Aldosterone System is a hormone system in the human body that is
| + | |
- | responsible for the regulation of blood pressure and fluid balance.</span></p>
| + | |
- | | + | |
- | <h3 style='text-align:justify'><span lang=EN-US>Functioning</span></h3>
| + | |
- | | + | |
- | <p class=MsoNormal style='text-align:justify'><span lang=EN-US>A decrease in
| + | |
- | renal perfusion causes the release of the enzyme renin which subsequently
| + | |
- | cleaves angiotensinogen to angiotensin I. This is further converted to
| + | |
- | angiotensin II by angiotensin-converting enzyme (ACE). The bioactive product,
| + | |
- | angiotensin II, causes the constriction of blood vessels, leading to an
| + | |
- | increased blood pressure. It is also responsible for the secretion of
| + | |
- | aldosterone by the adrenal cortex, which acts by increasing the re-absorption
| + | |
- | of sodium and water into the blood. Hence, the fluid volume as well as the
| + | |
- | blood pressure is maintained in the body.</span></p>
| + | |
- | | + | |
- | <h2><u><span lang=EN-US>The α-hemolysin System in <i style='mso-bidi-font-style:
| + | |
- | normal'>E.coli<o:p></o:p></i></span></u></h2>
| + | |
- | | + | |
- | <p class=MsoNormal><span lang=EN-US><o:p> </o:p></span></p>
| + | |
- | | + | |
- | <h3><span lang=EN-US>Introduction</span></h3>
| + | |
- | | + | |
- | <p class=MsoNormal style='text-align:justify'><span lang=EN-US>The
| + | |
- | alpha-hemolysin system is a type I secretion system found in wild type <i
| + | |
- | style='mso-bidi-font-style:normal'>E.coli </i>which enable them to cause
| + | |
- | infection in the urinary tract and is an important virulence factor because of
| + | |
- | its cytotoxic and cytolytic activity against a variety of mammalian cells. </span></p>
| + | |
- | | + | |
- | <h3 style='text-align:justify'><span lang=EN-US>Functioning</span></h3>
| + | |
- | | + | |
- | <p class=MsoNormal style='text-align:justify'><span lang=EN-US>The hemolysin
| + | |
- | system originates from a series of hly genes. These genes are present in the
| + | |
- | series <i style='mso-bidi-font-style:normal'>hlyC – hlyA – hlyB – hlyD</i>. Of
| + | |
- | these, <i style='mso-bidi-font-style:normal'>hlyA</i> codes for the protein
| + | |
- | that is responsible for the infection. Hly B and D are membrane proteins that
| + | |
- | work in coordination for the secretion of HlyA. The synthesis, activation and
| + | |
- | secretion of HlyA in <i style='mso-bidi-font-style:normal'>E.coli </i>is
| + | |
- | determined by the <i style='mso-bidi-font-style:normal'>hlyCABD</i> operon. This
| + | |
- | operon is either located either on the chromosome or on transmissible plasmids.
| + | |
- | | + | |
- | </span></p>
| + | |
- | | + | |
- | <p class=MsoNormal style='text-align:justify'><span lang=EN-US>It has been
| + | |
- | shown that this system can be used to produce and secrete a protein of our
| + | |
- | choice if the protein contains 60 amino acid residues from the carboxy terminal
| + | |
- | end of the HlyA protein. </span></p>
| + | |
- | | + | |
- | <h2><u><span lang=EN-US>Our iGEM 2010 Project<o:p></o:p></span></u></h2>
| + | |
- | | + | |
- | <p class=MsoNormal><span lang=EN-US><o:p> </o:p></span></p>
| + | |
- | | + | |
- | <h3><span lang=EN-US>Introduction</span></h3>
| + | |
- | | + | |
- | <p class=MsoNormal style='text-align:justify'><span lang=EN-US>Our aim is to
| + | |
- | create an online elicitor detection and response in a flow system, which can
| + | |
- | function in the detection of high blood pressure and help reduce it by
| + | |
- | releasing renin inhibitors into the circulatory system. This kind of a system
| + | |
- | would be helpful to patients with a hypertensive condition. </span></p>
| + | |
- | | + | |
- | <h3><span lang=EN-US>Approach</span></h3>
| + | |
- | | + | |
- | <p class=MsoNormal><span lang=EN-US>Since the blood pressure system is not
| + | |
- | really a chemical signal, what we have assumed is that the blood pressure can
| + | |
- | be easily converted into a chemical signal. Having assumed this, we will use a
| + | |
- | chemical signal such as IPTG or AHL as the elicitor to produce appropriate
| + | |
- | amounts of renin inhibitor. For easy detection and verification, we are
| + | |
- | planning to use GFP in place of renin inhibitor which can easily be replaced
| + | |
- | later.</span></p>
| + | |
- | | + | |
- | <p class=MsoNormal><span lang=EN-US>For this we will be introducing two vectors
| + | |
- | into <i style='mso-bidi-font-style:normal'>E. coli </i>as shown below.</span></p>
| + | |
- | | + | |
- | <p class=MsoNormal><span style='mso-ansi-language:EN-IN;mso-fareast-language:
| + | |
- | EN-IN;mso-bidi-language:HI;mso-no-proof:yes'><!--[if gte vml 1]><v:shapetype
| + | |
- | id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
| + | |
- | path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
| + | |
- | <v:stroke joinstyle="miter"/>
| + | |
- | <v:formulas>
| + | |
- | <v:f eqn="if lineDrawn pixelLineWidth 0"/>
| + | |
- | <v:f eqn="sum @0 1 0"/>
| + | |
- | <v:f eqn="sum 0 0 @1"/>
| + | |
- | <v:f eqn="prod @2 1 2"/>
| + | |
- | <v:f eqn="prod @3 21600 pixelWidth"/>
| + | |
- | <v:f eqn="prod @3 21600 pixelHeight"/>
| + | |
- | <v:f eqn="sum @0 0 1"/>
| + | |
- | <v:f eqn="prod @6 1 2"/>
| + | |
- | <v:f eqn="prod @7 21600 pixelWidth"/>
| + | |
- | <v:f eqn="sum @8 21600 0"/>
| + | |
- | <v:f eqn="prod @7 21600 pixelHeight"/>
| + | |
- | <v:f eqn="sum @10 21600 0"/>
| + | |
- | </v:formulas>
| + | |
- | <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
| + | |
- | <o:lock v:ext="edit" aspectratio="t"/>
| + | |
- | </v:shapetype><v:shape id="Picture_x0020_0" o:spid="_x0000_i1026" type="#_x0000_t75"
| + | |
- | alt="Vector1.png" style='width:195pt;height:209.25pt;visibility:visible;
| + | |
- | mso-wrap-style:square'>
| + | |
- | <v:imagedata src="IIT+Delhi+iGEM+Wiki_files/image001.png" o:title="Vector1"/>
| + | |
- | </v:shape><![endif]--><![if !vml]><img width=260 height=279
| + | |
- | src="IIT+Delhi+iGEM+Wiki_files/image002.gif" alt=Vector1.png v:shapes="Picture_x0020_0"><![endif]></span><span
| + | |
- | lang=EN-US><span style='mso-spacerun:yes'> </span><span
| + | |
- | style='mso-tab-count:1'> </span></span><span style='mso-ansi-language:
| + | |
- | EN-IN;mso-fareast-language:EN-IN;mso-bidi-language:HI;mso-no-proof:yes'><!--[if gte vml 1]><v:shape
| + | |
- | id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75" alt="Vector2.png"
| + | |
- | style='width:195pt;height:212.25pt;visibility:visible;mso-wrap-style:square'>
| + | |
- | <v:imagedata src="IIT+Delhi+iGEM+Wiki_files/image003.png" o:title="Vector2"/>
| + | |
- | </v:shape><![endif]--><![if !vml]><img width=260 height=283
| + | |
- | src="IIT+Delhi+iGEM+Wiki_files/image004.gif" alt=Vector2.png v:shapes="Picture_x0020_1"><![endif]></span></p>
| + | |
- | | + | |
- | <p class=MsoNormal><span lang=EN-US><o:p> </o:p></span></p>
| + | |
- | | + | |
- | <p class=MsoNormal style='text-align:justify'><span lang=EN-US>The first vector
| + | |
- | which contains the GFP-hlyA chimeric sequence with pLac promoter is used to
| + | |
- | produce the chimera GFP protein which contains 62 amino acid residues from the
| + | |
- | C terminal of hlyA protein, a prerequisite for the secretion of the protein
| + | |
- | outside the cell body. Forming a chimera will not in any way change the
| + | |
- | structure or function as per literature.</span></p>
| + | |
- | | + | |
- | <p class=MsoNormal><span lang=EN-US><o:p> </o:p></span></p>
| + | |
- | | + | |
- | <p class=MsoNormal><span lang=EN-US>The other vector contains the hlyB and hlyD
| + | |
- | sequences with ptet promoter sequence. These two proteins will be
| + | |
- | constitutively expressed. These proteins are present in the membrane and
| + | |
- | provide for an outlet of hlyA or chimeras with 62 amino acid residues of the C
| + | |
- | terminal of hlyA.</span></p>
| + | |
- | | + | |
- | <p class=MsoNormal><span lang=EN-US>After we are successful in obtaining
| + | |
- | GFP-hlyA chimera outside the cell body, our next task will be to immobilize
| + | |
- | these cells in a flow system and characterize the flow-expression profile. We
| + | |
- | would want to keep the cells in G0 phase so as to have continuous expression of
| + | |
- | the protein without cell death</span></p>
| + | |
- | | + | |
- | <p class=MsoNormal><span lang=EN-US>We will also be working towards minimizing
| + | |
- | the toxins and other products so that such a system can finally be thought fit
| + | |
- | for incorporating and integrating with the circulatory system in our body.</span></p>
| + | |
- | | + | |
- | <p class=MsoNormal><span lang=EN-US><o:p> </o:p></span></p>
| + | |
- | | + | |
- | <p class=MsoNormal style='text-align:justify'><span lang=EN-US><o:p> </o:p></span></p>
| + | |
| | | |
| + | <p><h2>Special comments:</h2> |
| + | 1.Plasmids acquired from Karolinska Institutet, Solna, Sweden. <br> |
| + | 2.Safety page in 'Work' link. |
| </div> | | </div> |
| | | |
Line 717: |
Line 567: |
| | | |
| </html> | | </html> |
- |
| |
- |
| |
- | {| style="color:#1b2c8a;background-color:#0c6;" cellpadding="3" cellspacing="1" border="1" bordercolor="#fff" width="62%" align="center"
| |
- | !align="center"|[[Team:IIT_Delhi_1|Home]]
| |
- | !align="center"|[[Team:IIT_Delhi_1/Team|Team]]
| |
- | !align="center"|[https://igem.org/Team.cgi?year=2010&team_name=IIT_Delhi_1 Official Team Profile]
| |
- | !align="center"|[[Team:IIT_Delhi_1/Project|Project]]
| |
- | !align="center"|[[Team:IIT_Delhi_1/Parts|Parts Submitted to the Registry]]
| |
- | !align="center"|[[Team:IIT_Delhi_1/Modeling|Modeling]]
| |
- | !align="center"|[[Team:IIT_Delhi_1/Notebook|Notebook]]
| |
- | !align="center"|[[Team:IIT_Delhi_1/Safety|Safety]]
| |
- | |}
| |